Acamprosate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Acamprosate
- ZaTxGNN Drug Repurposing Evidence Report: Acamprosate
- 1. Executive Summary
- 2. Drug Information
- 3. Predicted New Indications
- 4. Detailed Evidence Analysis by Indication
- 5. Safety Considerations
- 6. Data Gaps and Limitations
- 7. Recommendations
- 8. Evidence Level and Decision Stage Definitions
- 9. Query Log Summary
- Disclaimer
- Disclaimer
ZaTxGNN Drug Repurposing Evidence Report: Acamprosate
Candidate ID: ZA-DB00659-multi Report Version: v4 Date Generated: 2026-04-03 Data Cutoff: 2026-04-03
1. Executive Summary
This report evaluates Acamprosate (DrugBank ID: DB00659) as a drug repurposing candidate across 10 predicted novel indications generated by the TxGNN knowledge graph model. Acamprosate is a glutamate-modulating agent internationally approved for maintenance of abstinence in alcohol-dependent patients following detoxification.
Key Findings:
- Strongest candidate indication — Alcohol Withdrawal (Rank 9): Evidence Level L1 / Decision Stage S3 — supported by 7 clinical trials (including completed Phase 2–4 RCTs) and 19 PubMed publications. This represents a closely related extension of its approved indication with robust mechanistic rationale. Recommendation: Proceed with Guardrails.
- ADHD (Rank 7): Evidence Level L3 / Decision Stage S1 — supported by a completed Phase 2 pilot (n=14) in Fragile X syndrome youth and 3 publications. Evidence is subgroup-specific and cannot be generalised to primary ADHD. Recommendation: Research Question.
- Tourette Syndrome (Rank 6) and Trichotillomania (Rank 2): Moderate mechanistic rationale via glutamatergic pathways; however, the sole Tourette trial (NCT02217007) was withdrawn with zero enrolment. Recommendation: Research Question.
- Remaining 6 indications (DECR deficiency encephalopathy, Wernicke-Korsakoff syndrome, alcohol amnestic disorder, glaucoma, absence epilepsy, Aarskog syndrome): Evidence Level L4–L5, weak to absent mechanistic links. Recommendation: Hold.
SAHPRA Registration Status: Acamprosate is not currently registered with the South African Health Products Regulatory Authority (SAHPRA). It is not listed on the Essential Medicines List (EML) and is not available through South African public sector procurement channels.
Critical Data Gaps: SAHPRA labelling information (warnings/contraindications) and detailed mechanism of action data were not available at the time of this assessment.
2. Drug Information
| Parameter | Details |
|---|---|
| INN (Generic Name) | Acamprosate (calcium acetylhomotaurinate) |
| DrugBank ID | DB00659 |
| South African Brand Names | None — not marketed in South Africa |
| Chemical Class | Synthetic GABA analogue (calcium bis-acetyl-homotaurinate) |
| SAHPRA Registration | Not registered |
| Schedule Classification | Not scheduled (not registered with SAHPRA) |
| Essential Medicines List | Not listed on the South African EML (Adult, Paediatric, or PHC levels) |
| International Approvals | US FDA (2004, as Campral®); EMA; approved in >25 countries for maintenance of abstinence in alcohol dependence |
| Current Approved Indication | Maintenance of abstinence in alcohol-dependent patients who are abstinent at treatment initiation (international) |
| Mechanism of Action | [Data Gap] — Putative mechanism: functional antagonism at NMDA glutamate receptors; modulation of glutamatergic neurotransmission; reduction of neuronal hyperexcitability associated with chronic alcohol exposure. May also involve calcium-mediated effects and modulation of GABA-ergic tone. |
| Dosage Forms (International) | Enteric-coated tablets, 333 mg; typical dose 666 mg TID (1,998 mg/day) |
| Single Exit Price (SEP) | Not applicable — not marketed in South Africa |
Availability Considerations for South Africa
Acamprosate would need to be accessed via Section 21 application (unregistered medicines) to SAHPRA if required for individual patient use. There is currently no generic manufacture in South Africa. The Standard Treatment Guidelines (STGs) for alcohol use disorders in South Africa do not include acamprosate; current first-line pharmacotherapy for alcohol dependence in the public sector relies on benzodiazepines for withdrawal management and psychosocial interventions for relapse prevention.
3. Predicted New Indications
The TxGNN knowledge graph model generated 10 candidate indications for Acamprosate. These are ranked by TxGNN prediction score and stratified by evidence level and decision stage.
Summary Table
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Progressive encephalopathy with leukodystrophy (DECR deficiency) | 0.985 | L5 | S0 | Hold |
| 2 | Trichotillomania | 0.981 | L5 | S0 | Research Question |
| 3 | Wernicke-Korsakoff syndrome | 0.981 | L4 | S0 | Research Question |
| 4 | Alcohol amnestic disorder | 0.957 | L5 | S0 | Hold |
| 5 | Glaucoma | 0.943 | L5 | S0 | Hold |
| 6 | Tourette syndrome | 0.926 | L5 | S0 | Research Question |
| 7 | Attention deficit-hyperactivity disorder | 0.919 | L3 | S1 | Research Question |
| 8 | Absence epilepsy | 0.913 | L5 | S0 | Hold |
| 9 | Alcohol withdrawal | 0.906 | L1 | S3 | Proceed with Guardrails |
| 10 | Faciodigitogenital syndrome (Aarskog syndrome) | 0.904 | L5 | S0 | Hold |
Note on TxGNN Scores: Higher scores indicate stronger graph-based prediction confidence but do not equate to clinical validity. The highest-scoring indication (DECR deficiency, 0.985) has zero clinical evidence, while the indication with the richest evidence base (alcohol withdrawal, 0.906) ranks 9th. This underscores the importance of evidence triangulation.
4. Detailed Evidence Analysis by Indication
4.1 Alcohol Withdrawal (Rank 9) — ⭐ Lead Candidate
| **Evidence Level: L1 | Decision Stage: S3 | Recommendation: Proceed with Guardrails** |
Biological Rationale
The mechanistic link is strong. Alcohol withdrawal syndrome results from chronic ethanol-induced upregulation of NMDA receptors and downregulation of GABA-A receptors, leading to glutamatergic hyperexcitability upon cessation. Acamprosate acts as a functional NMDA antagonist that:
- Reduces glutamatergic hyperexcitability
- Restores excitatory/inhibitory neurotransmitter balance
- May attenuate withdrawal-associated neurotoxicity
This represents a direct mechanistic extension of its approved indication (maintenance of alcohol abstinence post-detoxification).
Clinical Trial Evidence
| NCT ID | Phase | Status | N | Design | Relevance |
|---|---|---|---|---|---|
| NCT03634917 | 3 | ✅ Completed | 82 | Double-blind, placebo-controlled, 3-arm RCT (Acamprosate vs Calcium vs Placebo) | Grade A — Direct validation of acamprosate efficacy; also tests calcium hypothesis |
| NCT00004552 | 2 | ✅ Completed | 120 | Pre-treatment with acamprosate prior to abstinence vs placebo | Grade A — Largest sample; directly evaluates withdrawal intensity reduction |
| NCT00330174 | 4 | ✅ Completed | 90 | Double-blind RCT in alcohol dependence with comorbid mood/anxiety | Grade A — Explores critical comorbidity scenario |
| NCT00106106 | 2 | ✅ Completed | 56 | Acamprosate for CNS hyperexcitability in alcohol withdrawal | Grade A — Mechanism-validating trial; directly tests neuroadaptation hypothesis |
| NCT00466661 | 4 | ✅ Completed | 33 | Double-blind RCT in alcohol dependence + bipolar disorder | Grade A — Rigorous design, comorbidity focus |
| NCT00855699 | 4 | ✅ Completed | 36 | Feasibility study of alcohol detoxification in primary care | Grade B — Implementation science focus |
| NCT02771925 | 4 | Terminated | 25 | Gabapentin trial (possible acamprosate comparator arm) | Grade B — Indirect; terminated early |
Total registered participants across trials: ~442
Published Literature (Selected Key Publications)
| PMID | Year | Type | Key Finding |
|---|---|---|---|
| 38747203 | 2024 | Clinical Guideline (GRACE-4) | SAEM guideline on ED management of alcohol withdrawal; references acamprosate in AUD management |
| 24825644 | 2014 | Systematic Review/Meta-analysis (JAMA) | Pharmacotherapy for alcohol use disorders in outpatient settings; comprehensive evaluation |
| 32696076 | 2021 | Review (Der Nervenarzt) | Update on pharmacotherapy of alcohol withdrawal; positions acamprosate among approved agents |
| 11524307 | 2001 | RCT (Alcohol and Alcoholism) | n=296, multicentre double-blind RCT in Spain; acamprosate from start of withdrawal rather than post-detox |
| 38741835 | 2024 | Prospective study (Cureus) | 12-week comparison of acamprosate vs baclofen as anti-craving agents |
| 29617889 | 2018 | IPD Meta-analysis | Acamprosate effect on insomnia in alcohol-dependent patients |
| 33567423 | 2021 | RCT | Calcium carbonate vs acamprosate; supports calcium component hypothesis |
Total relevant publications identified: 19
South African Context
Alcohol use disorders represent a significant burden of disease in South Africa. The 2016 South African Demographic and Health Survey estimated harmful alcohol use prevalence at approximately 31% among male drinkers. Alcohol withdrawal syndrome is frequently managed in public sector emergency departments. Current STG management relies on benzodiazepine-based detoxification protocols. Acamprosate could offer a non-benzodiazepine adjunctive approach, particularly relevant given concerns about benzodiazepine diversion and dependence.
Assessment
This indication has the strongest evidence base in the pack, with L1-level evidence from multiple completed RCTs and systematic reviews. The mechanistic rationale is directly aligned with acamprosate’s known pharmacology. However, this is a close extension of its existing approved indication rather than a true novel repurposing. Regulatory pathway considerations for SAHPRA would focus on indication extension rather than de novo approval.
4.2 Attention Deficit-Hyperactivity Disorder (Rank 7)
| **Evidence Level: L3 | Decision Stage: S1 | Recommendation: Research Question** |
Biological Rationale
Moderate-to-strong rationale within the Fragile X syndrome subgroup. Fragile X syndrome (FXS) involves excessive mGluR5 activation (the “mGluR theory”), and acamprosate may modulate mGluR5 signalling to improve FXS-associated ADHD symptoms. However, this mechanism is not generalisable to primary/idiopathic ADHD.
Clinical Trial Evidence
| NCT ID | Phase | Status | N | Key Details |
|---|---|---|---|---|
| NCT01300923 | 2 | ✅ Completed | 14 | Pilot study in Fragile X youth; open-label; showed partial behavioural improvement |
| NCT02217007 | 2 | Withdrawn | 0 | Tourette syndrome trial; tangentially relevant to ADHD comorbidity |
Literature
- Hagerman & Polussa (2015, PMID: 25602250): Review of psychiatric treatment in FXS, including ADHD symptoms
- Two additional reviews on pharmacotherapy of substance dependence with indirect ADHD relevance
Assessment
Evidence is restricted to the FXS-ADHD phenotype with very small sample sizes (n=14) and open-label design. Extrapolation to primary ADHD is not supported. This represents an interesting research question within the rare disease/neurodevelopmental space but is not actionable for general ADHD treatment in South Africa, where methylphenidate remains the EML-listed first-line agent.
4.3 Tourette Syndrome (Rank 6)
| **Evidence Level: L5 | Decision Stage: S0 | Recommendation: Research Question** |
Biological Rationale
Moderate. Tourette syndrome involves basal ganglia–cortical–thalamic circuit dysfunction with glutamatergic signalling abnormalities implicated in tic generation. NMDA receptor modulation could theoretically influence striatal dopamine-glutamate interactions.
Clinical Trial Evidence
| NCT ID | Phase | Status | N | Key Details |
|---|---|---|---|---|
| NCT02217007 | 2a | Withdrawn | 0 | SNC-102 (acamprosate calcium SR) in adult Tourette syndrome; BID dosing for 8 weeks; zero enrolment |
Assessment
The existence of a registered Phase 2a trial validates that the scientific community considered this hypothesis worth testing. However, the trial’s withdrawal with zero enrolment means no clinical data were generated. The mechanistic rationale remains speculative. Withdrawal may reflect recruitment difficulties, funding constraints, or unfavourable preclinical signals — the reason is not documented. This remains a theoretical research question only.
4.4 Trichotillomania (Rank 2)
| **Evidence Level: L5 | Decision Stage: S0 | Recommendation: Research Question** |
Biological Rationale
Moderate (indirect inference). Trichotillomania is an OCD-spectrum disorder where glutamatergic dysregulation has been implicated. N-acetylcysteine (another glutamate modulator) has shown efficacy in RCTs for trichotillomania (Grant et al. 2009, PMID: 19581567). Acamprosate’s NMDA modulation could potentially act via similar cortico-striatal-thalamic glutamate rebalancing.
Clinical Evidence
None. No clinical trials or publications were identified for acamprosate in trichotillomania.
Assessment
The mechanistic analogy with N-acetylcysteine is interesting but entirely hypothetical for acamprosate. Preclinical studies would be needed before any clinical investigation.
4.5 Wernicke-Korsakoff Syndrome (Rank 3)
| **Evidence Level: L4 | Decision Stage: S0 | Recommendation: Research Question** |
Biological Rationale
Moderate. WKS results from thiamine deficiency due to chronic alcoholism, with glutamate excitotoxicity contributing to neuronal damage in the thalamus and mammillary bodies. Acamprosate’s NMDA antagonism could theoretically provide neuroprotection. Additionally, acamprosate’s use in maintaining alcohol abstinence could indirectly prevent WKS recurrence. Critical limitation: Acamprosate cannot replace thiamine supplementation, which is the definitive treatment.
Literature
One review article identified (PMID: 17716602, 2007): General psychiatric management of alcohol dependence, which contextually mentions WKS.
South African Context
WKS is encountered in South African public hospitals, particularly among patients with chronic alcohol dependence and nutritional deficiency. Thiamine replacement remains the cornerstone; acamprosate’s role would be purely adjunctive and secondary.
4.6 Remaining “Hold” Indications (Ranks 1, 4, 5, 8, 10)
| Indication | Mechanistic Link | Key Concern | Status |
|---|---|---|---|
| DECR deficiency encephalopathy | Very weak — mitochondrial fatty acid β-oxidation defect unrelated to glutamate modulation | Likely statistical artefact from rare disease node bias in KG | Hold |
| Alcohol amnestic disorder | Moderate (indirect) — hippocampal/prefrontal damage with glutamate excitotoxicity | Overlaps clinically with WKS; no direct evidence | Hold |
| Glaucoma | Weak-to-moderate — retinal ganglion cell death involves glutamate excitotoxicity | Memantine (another NMDA antagonist) failed Phase 3 for glaucoma neuroprotection; poor ocular bioavailability expected with systemic acamprosate | Hold |
| Absence epilepsy | Weak with safety concern — glutamatergic modulators may lower seizure threshold or paradoxically worsen absence seizures | Do not advance without safety data | Hold |
| Aarskog syndrome | Very weak — FGD1 gene/Rho GTPase pathway unrelated to NMDA modulation | Likely false positive | Hold |
5. Safety Considerations
5.1 Known Adverse Effects (International Data)
⚠️ Data Gap: SAHPRA labelling information is not available as acamprosate is not registered in South Africa. The following is based on international regulatory data (US FDA, EMA).
Common (≥5%):
- Diarrhoea (most frequent; dose-related)
- Nausea, flatulence, abdominal pain
- Headache, dizziness
- Insomnia, anxiety
- Pruritus, asthenia
Serious but Rare:
- Suicidal ideation (post-marketing reports; causal relationship not established)
- Hypersensitivity reactions
- Renal impairment exacerbation
5.2 Contraindications
| Contraindication | Detail |
|---|---|
| [Data Gap] | Full SAHPRA contraindication data unavailable |
| Severe renal impairment | CrCl ≤30 mL/min (international labelling) |
| Hypersensitivity | To acamprosate calcium or excipients |
| Pregnancy/Lactation | Category C (US); avoid unless benefits outweigh risks |
5.3 Drug Interactions Relevant to South African Prescribing
| Interaction | Clinical Significance |
|---|---|
| Naltrexone | Often co-prescribed in AUD; combined use increases acamprosate Cmax by ~25% but is generally considered safe |
| Disulfiram | No significant pharmacokinetic interaction; may be used concomitantly |
| Benzodiazepines | No documented interaction; relevant given SA STG benzodiazepine-based withdrawal protocols |
| Antiretrovirals (ARVs) | No documented interactions with efavirenz, dolutegravir, or tenofovir-based regimens — important consideration given high HIV/ART prevalence in South Africa |
| TB medications | No documented interactions with rifampicin or isoniazid, though formal studies are lacking |
Note: Drug-drug interaction data for this compound were returned as “not_found” in the evidence pack. The above is based on general pharmacological knowledge and international references.
5.4 Adverse Drug Reaction Reporting
Healthcare professionals in South Africa should report suspected adverse drug reactions to:
- SAHPRA Pharmacovigilance Centre
- National Adverse Drug Event Monitoring Centre (NADEMC), University of Cape Town
- Reporting form: MedWatch-equivalent on SAHPRA website
- This is especially important for an unregistered medicine accessed via Section 21
6. Data Gaps and Limitations
| Gap ID | Category | Item | Severity | Impact | Remediation |
|---|---|---|---|---|---|
| DG001 | Drug Level | SAHPRA label warnings/contraindications | Blocking | Cannot proceed to S1 safety assessment | Query SAHPRA database or obtain package insert via Section 21 application |
| DG002 | Drug Level | Full mechanism of action | High | Limits mechanistic linkage analysis | Query DrugBank API for complete MOA data |
| — | Regulatory | SAHPRA registration status details | Medium | No local regulatory pathway assessed | Submit regulatory intelligence query to SAHPRA |
| — | Evidence | South African clinical studies | Medium | No local population data | Search SANCTR (South African National Clinical Trials Register) and Pan African CTR |
| — | Evidence | ICTRP trial data | Low | No additional international trial data found | All ICTRP queries returned zero results |
| — | Pharmacoeconomic | Cost-effectiveness in SA context | Medium | Cannot assess SEP or budget impact | Would require health economic modelling |
7. Recommendations
7.1 Evidence Strength Assessment
| Tier | Indications | Action |
|---|---|---|
| Tier 1 — Actionable | Alcohol withdrawal | Proceed with regulatory pathway assessment; consider SAHPRA Section 21 access for clinical use; identify SA trial sites |
| Tier 2 — Investigational | ADHD (Fragile X subgroup), Tourette syndrome, Trichotillomania, Wernicke-Korsakoff syndrome | Formulate as research questions; seek preclinical/early clinical data |
| Tier 3 — Archive | DECR deficiency, Alcohol amnestic disorder, Glaucoma, Absence epilepsy, Aarskog syndrome | Insufficient evidence and/or safety concerns; no further action recommended |
7.2 Suggested Next Steps
For Alcohol Withdrawal (Lead Candidate):
- Regulatory Intelligence: Determine whether any pharmaceutical company has submitted or plans to submit a SAHPRA registration application for acamprosate
- Section 21 Access: Establish a Section 21 unregistered medicine access pathway for compassionate/clinical use in alcohol withdrawal management at SA academic centres
- Local Clinical Trial: Design a pragmatic randomised trial comparing acamprosate-augmented vs standard benzodiazepine-only detoxification protocols in SA public hospital settings
- Pharmacoeconomic Analysis: Model cost-effectiveness relative to current STG management, considering potential reductions in ICU admissions for severe withdrawal complications
- EML Consideration: If clinical evidence supports efficacy, prepare a dossier for National Essential Medicines List Committee (NEMLC) review
For Research Question Indications:
- Fragile X/ADHD: Engage with the Division of Human Genetics at the National Health Laboratory Service (NHLS) and the University of Cape Town Department of Psychiatry to assess interest in a South African Fragile X treatment study
- Tourette Syndrome: Monitor international literature for any new trials; consider collaboration with the South African Society of Psychiatrists (SASOP) Neuropsychiatry Special Interest Group
7.3 Relevant South African Research Institutions
| Institution | Relevance |
|---|---|
| South African Medical Research Council (SAMRC) | Alcohol and substance abuse research programme |
| University of Cape Town — Department of Psychiatry & Mental Health | Addiction research; clinical trials infrastructure |
| University of Stellenbosch — Department of Psychiatry | Neuropsychiatric genetics; Tourette/OCD research |
| University of the Witwatersrand — Perinatal HIV Research Unit | Trial execution capacity; pharmacovigilance |
| SAHPRA Clinical Trials Committee | Regulatory approval for local trials |
| National Health Laboratory Service (NHLS) | Genetic testing infrastructure for rare disease indications |
7.4 Public Health Implications
South Africa bears one of the highest burdens of alcohol-related harm globally. The Western Cape, Gauteng, and KwaZulu-Natal provinces have particularly high rates of alcohol use disorders. Access to evidence-based pharmacotherapy for alcohol withdrawal and relapse prevention is limited in the public sector, with benzodiazepines being the primary pharmacological intervention.
Introduction of acamprosate into the South African therapeutic armamentarium could:
- Provide a non-controlled substance option for alcohol relapse prevention
- Reduce benzodiazepine prescribing burden and associated risks
- Align with WHO mhGAP intervention guidelines for alcohol use disorders
- Address a significant gap in the current Essential Medicines List
However, barriers include:
- Absence of SAHPRA registration (would require investment from a pharmaceutical applicant or government initiative)
- Cost considerations for public sector procurement
- Limited specialist addiction medicine capacity at primary care level
- Need for local clinical data in South African populations
8. Evidence Level and Decision Stage Definitions
| Level | Definition |
|---|---|
| L1 | Systematic review/meta-analysis or clinical guideline with direct evidence |
| L2 | Randomised controlled trial(s) |
| L3 | Non-randomised studies, small pilot trials, or case series |
| L4 | Case reports or narrative reviews with indirect evidence |
| L5 | Computational prediction only; no clinical evidence |
| Stage | Definition |
|---|---|
| S0 | Computational prediction — not yet assessed for safety |
| S1 | Safety screening initiated |
| S2 | Preclinical/early clinical evaluation |
| S3 | Clinical evidence sufficient for risk-benefit assessment |
9. Query Log Summary
| Source | Total Queries | Queries with Results | Total Results |
|---|---|---|---|
| DrugBank | 1 | 1 | 1 |
| ClinicalTrials.gov | 10 | 3 | 10 trials |
| ICTRP | 10 | 0 | 0 |
| PubMed | 10 | 3 | 23 publications |
| SANCTR | Not queried | — | — |
| Pan African CTR | Not queried | — | — |
Note: South African National Clinical Trials Register (SANCTR) and Pan African Clinical Trials Registry were not queried in this evidence pack. These should be consulted in subsequent updates.
Disclaimer
Research Use Only: This report is generated for research purposes only and does not constitute medical advice. Drug repurposing predictions require clinical validation before therapeutic application. This is not a SAHPRA-approved assessment. Always refer to current Standard Treatment Guidelines and the Essential Medicines List. Healthcare professionals should exercise independent clinical judgement. Any use of acamprosate in South Africa for indications described in this report would require appropriate SAHPRA authorisation (including Section 21 access for unregistered medicines). Adverse events should be reported to SAHPRA’s pharmacovigilance programme.
Generated by ZaTxGNN — South Africa Drug Repurposing Predictions Report ID: ZA-DB00659-multi-v4 | Model: TxGNN Knowledge Graph + Evidence Triangulation Data sources: DrugBank, ClinicalTrials.gov, PubMed, ICTRP
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.